Hikal [HIKAL] vs Aarti Pharmalabs [AARTIPHARM] Detailed Stock Comparison

Hikal

NSE
Loading...

Aarti Pharmalabs

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Hikal wins in 6 metrics, Aarti Pharmalabs wins in 13 metrics, with 0 ties. Aarti Pharmalabs appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricHikalAarti PharmalabsBetter
P/E Ratio (TTM)50.9930.03Aarti Pharmalabs
Price-to-Book Ratio2.564.02Hikal
Debt-to-Equity Ratio60.5820.76Aarti Pharmalabs
PEG Ratio-0.09-2.78Aarti Pharmalabs
EV/EBITDA13.3818.02Hikal
Profit Margin (TTM)3.45%13.69%Aarti Pharmalabs
Operating Margin (TTM)-3.76%18.76%Aarti Pharmalabs
EBITDA Margin (TTM)N/A18.76%N/A
Return on Equity7.19%13.69%Aarti Pharmalabs
Return on Assets (TTM)3.59%9.37%Aarti Pharmalabs
Free Cash Flow (TTM)$1.43B$-1.12BHikal
Dividend Yield0.74%0.40%Hikal
1-Year Return-34.40%33.81%Aarti Pharmalabs
Price-to-Sales Ratio (TTM)1.764.12Hikal
Enterprise Value$39.78B$83.59BAarti Pharmalabs
EV/Revenue Ratio2.174.30Hikal
Gross Profit Margin (TTM)49.69%56.13%Aarti Pharmalabs
Revenue per Share (TTM)$149$215Aarti Pharmalabs
Earnings per Share (Diluted)$5.14$29.39Aarti Pharmalabs
Beta (Stock Volatility)0.45-0.50Aarti Pharmalabs
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Hikal vs Aarti Pharmalabs Stock Performance Analysis

Loading Price Chart...

Hikal
Aarti Pharmalabs
Hikal Stock Overview | Aarti Pharmalabs Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Hikal1.60%1.25%-10.67%-30.89%-29.98%-35.56%
Aarti Pharmalabs2.84%2.43%4.18%-3.24%17.96%26.06%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Hikal-34.40%-27.56%36.96%273.36%319.73%198.70%
Aarti Pharmalabs33.81%239.73%239.73%239.73%239.73%239.73%

News Based Sentiment: Hikal vs Aarti Pharmalabs

Hikal

News based Sentiment: MIXED

Hikal is facing short-term headwinds in its pharmaceutical division, as evidenced by the Q1 FY26 performance, but is actively responding with strategic initiatives like CDMO expansion and diversification. The consistent dividend payments and stable financial ratios provide a degree of stability, but the declining EPS trend warrants caution, creating a mixed investment narrative.

View Hikal News Sentiment Analysis

Aarti Pharmalabs

News based Sentiment: POSITIVE

Aarti Pharmalabs demonstrated strong operational and financial developments in September 2025, including the commissioning of a new manufacturing facility, a dividend announcement, and positive share price movement. While analyst coverage is limited, existing forecasts are bullish, suggesting a positive outlook for the company and its investors.

View Aarti Pharmalabs News Sentiment Analysis

Performance & Financial Health Analysis: Hikal vs Aarti Pharmalabs

MetricHIKALAARTIPHARM
Market Information
Market Cap i₹32.33B₹83.46B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i495,182242,508
90 Day Avg. Volume i504,948353,823
Last Close₹263.75₹906.65
52 Week Range₹245.00 - ₹464.75₹557.05 - ₹971.00
% from 52W High-43.25%-6.63%
All-Time High₹742.00 (Aug 16, 2021)₹971.00 (Jul 16, 2025)
% from All-Time High-64.45%-6.63%
Growth Metrics
Quarterly Revenue Growth-0.07%-0.31%
Quarterly Earnings Growth-0.08%-0.11%
Financial Health
Profit Margin (TTM) i0.03%0.14%
Operating Margin (TTM) i-0.04%0.19%
Return on Equity (TTM) i0.07%0.14%
Debt to Equity (MRQ) i60.5820.76
Cash & Liquidity
Book Value per Share (MRQ)₹102.34₹219.62
Cash per Share (MRQ)₹1.46₹6.20
Operating Cash Flow (TTM) i₹1.54B₹3.51B
Levered Free Cash Flow (TTM) i₹908.00M₹2.72B
Dividends
Last 12-Month Dividend Yield i0.74%0.40%
Last 12-Month Dividend i₹2.00₹3.50

Valuation & Enterprise Metrics Analysis: Hikal vs Aarti Pharmalabs

MetricHIKALAARTIPHARM
Price Ratios
P/E Ratio (TTM) i50.9930.03
Forward P/E i20.40N/A
PEG Ratio i-0.09-2.78
Price to Sales (TTM) i1.764.12
Price to Book (MRQ) i2.564.02
Market Capitalization
Market Capitalization i₹32.33B₹83.46B
Enterprise Value i₹39.78B₹83.59B
Enterprise Value Metrics
Enterprise to Revenue i2.174.30
Enterprise to EBITDA i13.3818.02
Risk & Other Metrics
Beta i0.45-0.50
Book Value per Share (MRQ) i₹102.34₹219.62

Financial Statements Comparison: Hikal vs Aarti Pharmalabs

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)HIKALAARTIPHARM
Revenue/Sales i₹5.50B₹5.64B
Cost of Goods Sold i₹2.32B₹2.79B
Gross Profit i₹3.18B₹2.85B
Research & Development iN/AN/A
Operating Income (EBIT) i₹857.00M₹1.23B
EBITDA i₹1.24B₹1.44B
Pre-Tax Income i₹683.00M₹1.15B
Income Tax i₹181.00M₹262.81M
Net Income (Profit) i₹502.00M₹883.39M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)HIKALAARTIPHARM
Cash & Equivalents i₹130.00M₹67.34M
Total Current Assets i₹9.95B₹13.22B
Total Current Liabilities i₹7.90B₹6.57B
Long-Term Debt i₹3.70B₹1.15B
Total Shareholders Equity i₹12.62B₹19.90B
Retained Earnings iN/AN/A
Property, Plant & Equipment i₹13.57B₹11.04B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)HIKALAARTIPHARM
Operating Cash Flow iN/A₹522.01M
Capital Expenditures iN/A₹-331.51M
Free Cash Flow iN/A₹702.37M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricHIKALAARTIPHARM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i495,182242,508
Average Daily Volume (90 Day) i504,948353,823
Shares Outstanding i123.30M90.63M
Float Shares i38.07M47.97M
% Held by Insiders i0.69%0.45%
% Held by Institutions i0.08%0.11%

Dividend Analysis & Yield Comparison: Hikal vs Aarti Pharmalabs

MetricHIKALAARTIPHARM
Last 12-Month Dividend i₹2.00₹3.50
Last 12-Month Dividend Yield i0.74%0.40%
3-Year Avg Annual Dividend i₹1.40₹2.11
3-Year Avg Dividend Yield i0.20%0.24%
3-Year Total Dividends i₹4.20₹6.34
Ex-Dividend DateSep 02, 2025Feb 14, 2025